In November 2017, Asana Medical, Inc. announced that they had formally changed their name to Regentys, as a more distinctive representation of their business model and underlying regenerative medicine technology.

IBD NEWS DAILY: Asana Reports Positive Preclinical Data of Treatment for Ulcerative Colitis

Oct. 17, 2016

Asana Medical has announced positive data from a preclinical study using an innovative liquid treatment called Extracellular Matrix Hydrogel (ECMH)

Read More →

Asana Medical Inc.’s Preclinical Study Indicates Promising Solution to Treat Ulcerative Colitis

Oct. 4, 2016

Company’s Patented Drug-Free, Non-Surgical Therapy Promotes Tissue Regeneration

Read More →

Asana Medical, Inc. CEO Dr. Christine V. Sapan to Present at 2016 BIO International Convention June 8th

June 1, 2016

Sapan to Provide Data Findings and Analysis from Company’s Recent Pivotal Preclinical Study

Read More →

Asana Medical, Inc. Adds Dr. Hal K. Wrigley to Board of Directors

May 18, 2016

Dr. Hal Wrigley, a dentist by trade and entrepreneur, has joined the Company’s Board of Directors.

Read More →

Asana Medical, Inc. Announces Closing of $1.2 Million Convertible Promissory Note Offering

May 10, 2016

Asana has closed a $1.2 million offering of convertible promissory notes. Asana, an emerging life sciences company, is focused on the development and commercialization of an innovative therapy to non-surgically treat Inflammatory Bowel Diseases (“IBD”), including Ulcerative Colitis (“UC”), Crohn’s Disease and Rectal Mucositis.

Read More →